Kornimate/medical-research-clean huggingface dataset:
atenolol exposure as risk for adverse metabolic responses to beta blockers

Conditions: Hypertension

Summary: the researchers hypothesize that the impact of increasing systemic exposure to atenolol leads to increased risk for adverse metabolic effects from atenolol therapy in hypertension. this will be accomplished through a 24-hour pharmacokinetic (pk) study and oral glucose tolerance test in hypertensive patients taking chronic atenolol 100 mg daily.

the current study is a sub-study of pharmacogenomic evaluation of antihypertensive responses (pear - nct00246519). the primary objective of this pharmacokinetic (pk) study is to investigate the correlation of atenolol cp with hypertriglyceridemia and insulin sensitivity in mild to moderate hypertensive patients after 6-8 weeks of atenolol treatment. participants will undergo the pk study when they have been on atenolol 100 mg once daily for at least 4 weeks and on atenolol therapy (50 mg or 100 mg) for ≥ 7 weeks. they will undergo a two hour oral glucose tolerance test (ogtt), 1 hour after atenolol dosing. blood will be drawn at 12 time points for 24 hours. atenolol cp will be measured in all 12 blood samples and will be correlated with the glucose/insulin measured during the ogtt.

Eligibility criteria:
inclusion criteria: * subjects from pear who are on atenolol 100 mg once daily will be invited to participate * other inclusion criteria from pear exclusion criteria: * patients with bmi \>35 kg/m2 will be excluded * other exclusion criteria from pear

Keywords: keywords by national institute of general medical sciences hypertension adverse metabolic effects beta blockers dyslipidemia atenolol new onset diabetes pharmacokinetic study oral glucose tolerance test
a rollover study for subjects participating in the control arm of study vx06-950-106, vx05-950-104 and vx05-950-104eu whose plasma hepatitis c virus (hcv) ribonucleic acid (rna) levels did not respond to therapy

Conditions: Hepatitis C

Summary: to provide access to a telaprevir-based treatment to subjects of the control group of study vx06-950-106 (nct00420784), vx05-950-104 (nct00336479), and vx05-950-104eu (nct00372385) who stopped treatment due to inadequate response to treatment. safety, tolerability, and hepatitis c virus (hcv) ribonucleic acid (rna) levels will be collected.


Eligibility criteria:
inclusion criteria: * enrolled in the control arm of study vx06-950-106 (nct00420784), vx05-950-104 (nct00336479) or vx05-950-104eu (nct00372385)

Keywords: genotype 1
cholecalciferol in newly diagnosed non-hodgkin lymphoma or chronic lymphocytic leukemia with vitamin d deficiency

Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma; Untreated Chronic Lymphocytic Leukemia; Vitamin D Deficiency

Summary: this randomized pilot early phase i trial studies how well cholecalciferol works in treating patients with newly diagnosed non-hodgkin lymphoma or chronic lymphocytic leukemia with low levels of vitamin d (vitamin d deficiency). cholecalciferol may increase levels of vitamin d and improve survival in patients with non-hodgkin lymphoma or chronic lymphocytic leukemia receiving standard of care chemotherapy.

primary objectives: i. to evaluate the 3 year progression-free survival (pfs), defined as time from the time of study entry of watch and wait or newly diagnosed non-hodgkin lymphoma (nhl) or chronic lymphocytic leukemia (cll) until relapse, progression, or death from any cause. secondary objectives: i. to evaluate changes in the levels of serum vitamin d levels during therapy with daily oral vitamin d supplementation (cholecalciferol). ii. to evaluate the overall survival (os), defined as time from the time of study entry of watch and wait patients or newly diagnosed nhl or cll until death from any cause. outline: patients with low levels of vitamin d are randomized to 1 of 2 arms and patients with normal levels are assigned to arm iii. arm i: patients receive high-dose cholecalciferol orally (po) daily for 3 years in the absence of disease progression or unacceptable toxicity. arm ii: patients receive low-dose cholecalciferol po daily for 3 years in the absence of disease progression or unacceptable toxicity. arm iii: patients receive no intervention.

Eligibility criteria:
inclusion criteria: * patients must have histologically confirmed newly diagnosed or previously untreated (patients may be under no treatment ?wait and watch? or have received two cycles of chemotherapy or localized radiation therapy before going on this study) non-hodgkin?s lymphoma or cll * patients must have serum 25-hydroxyvitamin d (25\[oh\]d) drawn at time of enrollment; (note: subjects currently taking vitamin d supplements are eligible for screening) * simultaneous participation in other therapeutic clinical trials will be allowed * patients must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts exclusion criteria: * history of uncontrollable allergic reactions to vitamin d * history of paget?s disease * hypercalcemia * any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the investigator?s opinion, may interfere with protocol adherence or a subject?s ability to give informed consent * inability to cooperate with the requirements of the protocol
18f-dtbz for l diagnosis of parkinson's disease and monitoring the severity of disease by vmat2 pet imaging

Conditions: Parkinson's Disease

Summary: the primary objective of this protocol is to analyze the sensitivity and specificity of 18f-dtbz pet to the differential diagnosis of parkinson's disease (pd) and normality. secondary, the investigators will analyze the correlation between the 18f-dtbz binding and the severity of disease of pd and the role of 18f-dtbz pet in the monitoring disease severity.

25 age-matched healthy volunteers will be enrolled. for assessing the correlation between the 18f-dtbz binding and the severity of disease, the patients with pd will be divided into three groups according to their motor scores: mild, moderate, and advanced. we will enroll 25 patients in each group. each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study, as one screening visit, one imaging visit, and one safety evaluation visit. safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.

Eligibility criteria:
inclusion criteria: 1. both genders and 50\~80 years old. 2. written and dated informed consent by self or by legal representative, to be obtained before any of the study procedures 3. healthy male or female subjects with no evidence of significant neurologic impairment by history. 4. seventy-five pd subjects will be divided as three subgroups according to the severity of disease: mild (modified hoehn and yahr stage 1 to 2), moderate (modified hoehn and yahr stage 2.5 to 3), and advanced (modified hoehn and yahr stage 4 to 5). 5. all the pd subjects should be fulfilled the uk parkinson's disease society brain bank criteria of "possible" or "probable" pd. the age of disease onset should be older than 50 years. exclusion criteria: 1. pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the pi discretion) or current breast feeding. 2. any subject who has a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness. 3. history of drug or alcohol abuse within the last year, or prior prolonged history of abuse. 4. history or presence of qtc prolongation. 5. history of intracranial operation, including thalamotomy, pallidotomy, and/or deep brain stimulation. 6. any documented abnormality in the brain by ct or mri of brain, which might contribute to the motor function, such as hydrocephalus, multiple infarction and encephalomalacia, will be excluded. mild cortical atrophy and non-specific white matter changes will be allowed. 7. patients who have the evidence of secondary

Keywords: parkinson's disease
analyzing acoustic properties of the vowel "a" collected via mobile phone from individuals diagnosed with chronic obstructive pulmonary disease and health control groups

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the study aims to identify the changes in voice caused by chronic obstructive pulmonary disease (copd) statistically for identifying the potential digital voice biomarkers.

1058 voice recordings collected via mobile phones over time in form of the swedish utterance of vowel "a" will be analysed using vowel quadrilateral space and the mann-whitney u test. the significance threshold p-value will be set to 0.05, and vocal features consisting of 101 base line acoustic features and mfcc features will be analysed between the copd and hc groups. the most significant features that remain under the significance threshold will be reported.

Eligibility criteria:
inclusion criteria: * being 18 years old and older. exclusion criteria: * being under 18 years old and older.

Keywords: acoustic features statistic analysis mel frequency cepstral coefficients vowel quadrilateral
comparison of qpcr to ihc and fish for detection of alk fusion mutations in ffpe tissue from nsclc patients

Conditions: Nonsmall Cell Lung Cancer

Summary: the anaplastic lymphoma kinase gene(alk) is mutated approximately 5% of non-small cell lung cancers. testing for this gene is important because there are drugs known as alk inhibitors that have been shown to significantly delay the progression of alk-mutated lung cancers. there are a number of ways to test for the presence of the alk gene in lung cancer biopsy tissue. one method involves making slides and staining them to detect the alk protein. this is called immunohistochemistry. another method called fluorescence in situ hybridization(fish)is used to detect rearrangements of the alk gene associated with lung cancer. although both these tests are widely used to test for alk gene abnormalities, the techniques may not always find the alk gene mutation because they are not sensitive enough or not enough cancer cells are present in the lung biopsy. this study is being performed to determine if a technique called quantitation polymerase chain reaction (qpcr) is as accurate or better at finding the alk gene mutation in lung cancer biopsy tissue.


Eligibility criteria:
inclusion criteria: * you have a confirmed diagnosis of non-squamous, non-endocrine non-small cell lung cancer. * your cancer biopsy has sufficient cancer cells to be tested for the (epidermal growth factor receptor (egfr) mutation, the alk fusion gene abnormality and the research alk testing. * your lung cancer biopsy is determined not to have a mutation in the egfr gene. * you are 19 years old or older. * you fully understand the study and give informed consent to participate as demonstrated by signing the consent.

Keywords: anaplastic lymphoma kinase gene polymerase chain reaction immunohistochemistry fluorescence in situ hybridization
intravenous remifentanil patient-controlled analgesia (pca) and epidural patient controlled epidural analgesia (pcea) for labor analgesia

Conditions: Labor; Pain

Summary: women requesting analgesia do not always wish to receive a potent analgesic method, and may fear the risks of epidural analgesia. study aim: to determine whether remifentanil is effective for labor analgesia when compared with standard treatment (epidural analgesia).


Eligibility criteria:
inclusion criteria: * healthy women * american society of anesthesiologists physical status class i or ii * body weight less than 110 kg * in active labor (including induced labor and premature rupture of membranes) * cervical dilatation at 2-6 cm * regular contractions * age between 18 and 40 years old * gestational age greater than 36 completed weeks * singleton pregnancy and vertex presentation exclusion criteria: * contraindication for epidural analgesia (bleeding diathesis, neuropathy, severe scoliosis, previous spine surgery, local anesthetic allergy) * narcotic administration in the previous 2 hours * previous uterine surgery * pre-eclampsia and the inability to adequately understand the consent form * blocked nose, and any indication patient for whom epidural analgesia is medically indicated (cardiac disease, suspected difficult airway)

Keywords: epidural labor remifentanil
psychotherapy and pharmacotherapy in the treatment of erectile dysfunction: a pilot study

Conditions: Erectile Dysfunction

Summary: the study involved the administration of pharmacotherapy and cognitive behavior psychotherapy to individuals suffering from erectile dysfunction. the study was randomized controlled trial with two arms involving a control group. the study was conducted with an aim of pilot and feasibility study to evaluate the efficacy and suitability of cognitive behavior psychotherapy with individuals suffering from erectile dysfunction.


Eligibility criteria:
inclusion criteria: 1. men diagnosed with erectile dysfunction 2. must be in the age range of 18 to 39 years 3. must be in a stable heterosexual relationship 4. must not be suffering from any medical or psychiatric illness exclusion criteria: 1. men not meeting criteria of diagnosis of erectile dysfunction 2. men not in a heterosexual relationship 3. men of or above the age of 40 years 4. men diagnosed with any medical or psychiatric illness or obese men

Keywords: sexual dysfunctions, men health
treatment of gingival recessions with connective tissue or concentrated growth factor membrane using tunnel technique

Conditions: Gingival Recession

Summary: this randomized controlled clinical study aimed to evaluate the success of the combination of tunnel technique and concentrated growth factor membrane for root coverage in treating multiple gingival recessions and compare with the gold standard connective tissue graft.

the study included 108 defects in 40 patients with miller class i and ii gingival recession. gingival recession defects were randomly divided into two groups. tunnel technique + connective tissue graft was applied to 20 patients in the control group (51 defects) and tunnel technique + concentrated growth factor membrane was applied to 20 patients in the test group (57 defects). the results at baseline and 6 months were evaluated for the following clinical parameters: mean root coverage, complete root coverage, probing depth, clinical attachment level, gingival recession depth, gingival recession width, keratinized tissue width and gingival thickness.

Eligibility criteria:
inclusion criteria: * age ≥18 years * periodontally and systemically healthy * presence of miller i or ii class gingival recession defect in at least two teeth on the buccal aspect of incisors, canine and premolar teeth (≥ 2 mm in depth) * gingival thickness ≥ 0.8 mm 2 mm apical to the gingival margin * presence of identifiable cementoenamel junction (cej) (step ≤1 mm at the cej level and/or presence of a root irregularity/abrasion with identifiable cej was accepted * full-mouth plaque score (fmps) ≤20%. exclusion criteria: * smoking * contraindications for surgical periodontal treatment * presence of recession defects associated caries, restoration and furcation problems * use of systemic antibiotics for any reason in the last 3 months.
quantify the value of transmural inflammation in the treatment of crohn's disease with ustekinumab:an analysis based on imaging science

Conditions: Inflammatory Bowel Diseases; Crohn Disease; Biologics

Summary: crohn's disease(cd),a type of inflammatory bowel disease(ibd), is a chronic intestinal recurrent inflammatory disease involving the entire digestive tract. and ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, is a newly targeted drug approved for the treatment of crohn's disease in recent years.based on the high-throughput imaging characteristic analysis technique, this study quantitatively analyzed the transmural inflammation of crohn's disease, and discussed its prognostic value in the treatment of ustekinumab, and further analyzed the increment of its relative clinical index.


Eligibility criteria:
inclusion criteria: * inpatients with crohn's disease diagnosed in the ibd center of sixth affiliated hospital of sun yat-sen university from january 2020 to june 2022 * treated with ustekinumab and followed up regularly for 20 weeks * complete pre-treatment cross-sectional imaging data (cte/mre and us) exclusion criteria: * the diagnosis is not clear * under the age of 18 * lack of endoscopic and pathological data

Keywords: crohn disease biologics
stress and musculoskeletal health in employees

Conditions: Musculoskeletal Diseases or Conditions; Musculoskeletal Pain; Musculoskeletal Health; Stress; Work Related Stress; Occupation-related Stress Disorder; Medically Unexplained Symptoms

Summary: this study aims to evaluate potential correlation of stress as estimated by certain biological markers, namely saliva cortisol, heart rate variability (hrv), electromyography (emg) with musculoskeletal system health status, and assess the impact of a stress management intervention..the intervention group will be trained to apply two evidence based stress management techniques and they will be guided with tips and advice about musculoskeletal health. impact of the intervention upon measured stress related markers will be assessed.

the goal of this non-pharmacological randomized interventional study is to investigate work-related stress in relation to the musculoskeletal health of employees. the primary purpose of this study is to investigate if stress management interventions in employees can improve self-reported musculoskeletal health problems or medically unexplained symptoms (mus), in relation with biomarkers of stress. secondary outcomes will include quality of life improvement and the number of absences from work, due to musculoskeletal conditions. the main question aims to answer if specific stress management techniques can improve the self-reported musculoskeletal health of employees. researchers will compare the results between two groups (one participating in the the six (6) week program and the other not participating) to measure the effect size in the intervention group and between groups. participants from both groups will be measured twice (on week 1 and week 8) with the same self-report questionnaires and stress biomarkers, if possible. especially for the intervention group a six-week stress management program will be applied. this will include the participation in one and a half hour consultation meetings about stress, musculoskeletal health, psychosocial work-related factors, and how to improve well-being and work/life satisfaction.

Eligibility criteria:
inclusion criteria: * writing and reading greek. * consent to provide their medical history. * consent to be measured with electronic devices. exclusion criteria: * employees who are close to retirement (at least 2 years before) and those for whom any known factor may prevent them from completing the intervention (eg travel, transfer). * pregnancy. * pacemaker, history of seizures. * diagnosed musculoskeletal injury. * diagnosed diseases such as: osteoarthritis, autoimmune diseases (rheumatoid arthritis, lupus, etc.), stroke, myocardial infarction, malignant neoplasms, psychiatric disease, disability. * systematic reception of cortisone and anti-inflammatory treatment, up to at least three months before the intervention. * drugs or substances. * participation in another interventional program of musculoskeletal rehabilitation, physical therapy, stress management or health promotion.

Keywords: stress management stress biomarkers musculoskeletal health work-related biofeedback saliva cortisol hrv
set-back suture versus traditional vertical mattress suture

Conditions: Basal Cell Carcinoma; Squamous Cell Carcinoma; Melanoma

Summary: the investigators hope to compare two different methods of closing skin wounds using sutures. one of these methods (the set-back technique) was recently described in 2010 and has been reported to be technically easier and reduces the chance of spitting sutures (deep sutures that are pushed to the surface of the skin as the wound heals). the other method (the vertical mattress technique) has been used for many years with good results. however, no controlled studies have been performed to clearly demonstrate a difference between the two methods. we hope to find differences in the height of the wound edges immediately after surgery(5 minutes following the procedure) as well as the appearance of the scar and symptoms associated with the scar 3 months after surgery.


Eligibility criteria:
inclusion criteria: * elliptical surgical wound that needs to be closed with a layered closure * wound 3 cm in length or longer exclusion criteria: * incarceration * active pregnancy * less than 18 years of age * unable to give informed consent * non-english or dutch speaking (the scar assessment scale described below has only been validated in the english and dutch languages) * wound closure projected to be less than 3 cm in length * skin less than 3 mm in thickness (dermis and epidermis combined)
interscalene versus costoclavicular blocks for shoulder surgery

Conditions: Postoperative Pain; Shoulder Surgeries Operations; Regional Anesthesia; Costoclavicular Block; Interscalene Blocks

Summary: aim: shoulder surgeries are among the most painful surgical procedures in orthopedic practice. interscalene brachial plexus block, although the most commonly utilized regional anesthesia technique for alleviating pain following shoulder surgery, may result in complications such as hemidiaphragmatic paresis, hoarseness. more distal blocks along the brachial plexus may provide postoperative analgesia while potentially having less effect on respiratory functions. the aim of this study is to determine whether there are differences in postoperative pain scores and opioid consumption between interscalene block (isb) and costoclavicular brachial plexus block (ccb). materials and methods: following ethical approval, all eligible patients undergoing for shoulder surgery under general anesthesia between 01.11.2022 and 01.11.2023 will be enrolled and to be divided into two groups following written informed consent, with one group receiving isb and the other group receiving ccb. a blinded researcher will record pain scores at postoperative 0.5, 1, 6, 12, 18, and 24 hours. demographic data of patients, postoperative opioid consumption, time to first analgesic request, rescue analgesic requirements, adverse effects and hemodynamic parameters will be compared statistically.


Eligibility criteria:
inclusion criteria: * patients undergoing unilateral shoulder surgery * asa (american society of anesthesiology) class i, ii and iii patients exclusion criteria: * coagulopathy * chronic pulmoner disease * hypersensitivity to local anesthetics * ipsilateral neurological deficits * non-communicative patients

Keywords: analgesia brachial plexus postoperative pain shoulder surgery